Safety and Immunogenicity of a 9-Valent Human Papillomavirus Vaccine Administered to 9- to 15-Year-Old Japanese Girls
-
- Iwata Satoshi
- Keio University School of Medicine
-
- Murata Shinya
- MSD KK
-
- Rong Han Shi
- MSD KK
-
- Wakana Akira
- MSD KK
-
- Sawata Miyuki
- MSD KK
-
- Tanaka Yoshiyuki
- MSD KK
この論文をさがす
抄録
<p>A 9-valent human papillomavirus (HPV 6/11/16/18/31/33/45/52/58) virus-like particle vaccine (9vHPV) has been proven highly efficacious in preventing anogenital diseases related to HPV, in a pivotal phase III study for women aged 16-26 years. Here, we report the results of an open-label phase III study conducted to bridge the gap between the findings in women aged 16-26 years and Japanese girls aged 9-15 years. All subjects (n = 100) received a 3-dose regimen of 9vHPV vaccine on day 1 and at months 2 and 6. Anti-HPV serological assays were performed on day 1 and at months 7, 12, 24, and 30. At month 7 (4 weeks after the third dose), 100% of the subjects exhibited seroconversion for each type of HPV. Increases in geometric mean of the titers for anti-HPV 6/11/16/18/31/33/45/52/58 in the subjects were similar to those in Japanese women aged 16-26 years in a previous phase III study. Persistence of the anti-HPV response was observed for 2 years after administration of the third dose. In addition, administration of the 9vHPV vaccine was generally well-tolerated in Japanese girls.</p>
収録刊行物
-
- Japanese Journal of Infectious Diseases
-
Japanese Journal of Infectious Diseases 70 (4), 368-373, 2017
国立感染症研究所 Japanese Journal of Infectious Diseases 編集委員会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001206239582080
-
- NII論文ID
- 130005851899
-
- NII書誌ID
- AA1132885X
-
- ISSN
- 18842836
- 13446304
-
- NDL書誌ID
- 028402914
-
- PubMed
- 28003597
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可